INFI News and Press, Infinity Pharmaceuticals Inc. From 02/11/21

Infinity Pharmaceuticals (INFI) traded 4% down after hours post commencing an underwritten public offering; underwriters granted 30-day option to purchase an additional 15% of the shares.Offer size, terms not yet disclosed.Proceeds to be used for the continued clinical dev...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology macrophage reprogramming therapeutic candidate, which is designed to address a fundamental biol...

Shares of biotech company Infinity Pharmaceuticals (NASDAQ: INFI) are soaring through the roof on Thursday following the company's release of data from a phase 2 clinical trial for one of its pipeline candidates. As of 12:03 p.m. EST, the drugmaker's stock was up by 21%, after jumpi...

These Penny Stocks Are Jumping After Big News This Week Some of the biggest things traders look for when it comes to penny stocks are catalysts. This may come in the form of what we saw with GameStop and AMC; technical. But you’ve also got the other side of this coin, which i...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, tod...

AC Immune SA (ACIU) +112% as its vaccine generates potent anti-pTau antibody response in a phase 1b/2a study.RCM Technologies, Inc. (RCMT) +92%.Sundial Growers Inc. (SNDL) +48%.MicroVision, Inc. (MVIS) +44% after long range lidar update.Monopar Therapeutics (MNPR) +41% on poten...

Infinity Pharmaceuticals (INFI) rises 22% premarket following data from Phase 2 MARIO-275 (MAcrophage Reprogramming in Immune Oncology) study, evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo) in platinum-refractory, I/O naïve patients with...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, t...

Infinity Pharmaceuticals ([[INFI]] -21.5%) is paring the ~36.4% gain it made yesterday with analysts attributing the drop to a summary of eganelisib data to be presented by the company at a virtual medical conference on Thursday.In January, Infinity announced that an Independent Dat...

Gainers: Applied UV (AUVI) +367%.Comstock Holding Companies (CHCI) +125%.KalVista Pharmaceuticals (KALV) +112%.Veru (VERU) +60%.Heat Biologics (HTBX) +58%.SemiLEDs (LEDS) +45%.U.S. Well Services (USWS) +41%.Tilray (TLRY) +41%.Eastside Distilling (EAST) +40%.FSD Pharma (HUGE) +35%.Lo...